Letter to the Editor in response to the Carlomagno et al. article regarding the serum sST2 and IL-33 levels in patients with PAH

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 2920-2921

  Wang, Qian ^a   Wang, Chao ^b  

^a Hefei Center for Disease Control and Prevention   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

Endothelin 1; IL 33; Pulmonary arterial hypertension; ST2

Indexed keywords

CELL SURFACE RECEPTOR; INTERLEUKIN DERIVATIVE;

BLOOD; FEMALE; HUMAN; HYPERTENSION, PULMONARY; MALE;

FEMALE; HUMANS; HYPERTENSION, PULMONARY; INTERLEUKINS; MALE; RECEPTORS, CELL SURFACE;

EID: 84885637392     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.03.186     Document Type: Article

References (10)

1. G. Carlomagno, G. Messalli, and R.M. Melillo Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension Int J Cardiol 2013 10.1016/j.ijcard.2012.12.031
2. A. Giaid, M. Yanagisawa, and D. Langleben Expression of endothelin-1 in the lungs of patients with pulmonary hypertension N Engl J Med 328 1993 1732 1739
3. J. Dupuis Endothelin: setting the scene in PAH Eur Respir Rev 16 2007 3 7
4. S.H. Abman Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension Annu Rev Med 60 2009 13 23
5. A. Yndestad, A.K. Marshall, and J.D. Hodgkinson Modulation of interleukin signalling and gene expression in cardiac myocytes by endothelin-1 Int J Biochem Cell Biol 42 2010 263 272
6. A.M. Miller, and F.Y. Liew The IL-33/ST2 pathway - a new therapeutic target in cardiovascular disease Pharmacol Ther 131 2011 179 186
7. S. Wang, L. Ding, and S.S. Liu IL-33: a potential therapeutic target in autoimmune diseases J Investig Med 60 2012 1151 1156
8. O.S. Dhillon, H.K. Narayan, and P.A. Quinn Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP Am Heart J 161 2011 1163 1170
9. A.M. Miller, D. Purves, and A. McConnachie Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS One 7 2012 e47830
10. S. Willems, J.W. Sels, and S. Flier Temporal changes of soluble ST2 after cardiovascular interventions Eur J Clin Invest 43 2 2013 113 120